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Case report
The patient, a 39-year-old female with no family history 
of  breast cancer, initially presented with a palpable left 
breast mass. A breast ultrasound showed an irregular, solid, 
macrolobulated mass measuring 21.0 x 19.8 x 15.7 mm in 
the left breast at the 12 o'clock position. Internal echotex-
ture was heterogeneous, and microcalcifications and vascu-
larity were seen in the mass. The location of  the mass cor-
related to the palpable abnormality in the left breast, and 
the patient was categorized as BIRADS 4. On ultrasound, 
a lymph node measuring 12.4 x 12.8 x 7.8 mm was identi-
fied in the left axilla, and a lymph node measuring 11.2 x 
10.7 x 8.7 mm was identified in the right axilla. Both lymph 
nodes had imaging characteristics of  benign lesions. 
Subsequently, the patient underwent ultrasound-guided, 
vacuum-core biopsy of  the breast mass that identified 
poorly differentiated invasive ductal carcinoma (BIRADS 
6). The patient underwent bilateral breast MRI and a 
mammogram and was scheduled for surgery. On mammo-
gram, breasts were heterogeneously dense, and a mass with 
associated fine pleomorphic calcifications, linear calcifica-
tions, and punctate calcifications was seen in the left breast 
upper hemisphere at the 12 o'clock position. Anterior and 
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Previous studies have shown that an increased number of  axillary lymph nodes with metastatic involve-
ment is associated with nonvisualization of  lymph nodes during lymphoscintigraphy. We report a case of 
nonvisualization of  the sentinel node during lymphoscintigraphy in a female with advanced breast can-
cer to support this association. Although many factors can affect visualization of  the sentinel node dur-
ing lymphoscintigraphy, the presence of  advanced metastatic disease involving the lymphatic system 
must always be considered. 
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Figure 1A. 39-year-old woman with advanced breast cancer 
and nonvisualized sentinel node. Maximum-intensity projec-
tion (MIP) image from FDG PET scan demonstrating pri-
mary tumor in the left breast as well as left axillary lymph-
node involvement. 
lateral to the group of  malignant calcifications, there was a 
second small clustered group of  calcifications. In the right 
breast, no masses, significant calcifications, or other ab-
normalities were seen. Magnetic resonance imaging (MRI) 
of  the breasts showed three masses in the upper inner left 
breast. These masses included a 2.1 x 1.7-cm mass with 
spiculated margins in the 11 o’clock position, 8 cm from the 
nipple, which corresponded to the known malignancy. The 
two additional masses included a 9 x 9-mm enhancing mass  
in the 10 o’clock position of  the left breast, 7 cm from the 
nipple, and an adjacent 6 x 6-mm enhancing mass. The 
findings were suspicious for multifocal carcinoma. 
The patient underwent a PET-CT scan for staging. Ap-
proximately 50 minutes after the intravenous administra-
tion of  13.0 mCi of  FDG, whole-body PET-CT imaging 
was performed. The patient's blood glucose level was 86 
mg/dl at the time of  injection of  FDG. Images demon-
strated a dominant suspicious lobular soft-tissue mass in the 
upper inner quadrant of  the left breast measuring 1.9 cm, 
with a maximum SUV of  9.9. Two additional suspicious 
foci were seen more inferolaterally, at least one of  which 
had an anatomic correlate. These most likely corresponded 
to the abnormally enhancing foci on the recently per-
formed MRI of  the breasts and were consistent with multi-
focal involvement. Focal metabolic activity was noted corre-
sponding to a benign-appearing, 1.4 x 0.9-cm, low-lying left 
axillary lymph node (maximum SUV 1.6), and a 1.2-cm 
lymph node deep to the pectoralis minor muscle with 
maximum SUV 2.3 (Figs. 1A, 1B, 1C). These lymph nodes 
were suspicious for regional nodal metastases. There was no 
evidence of  suspicious right axillary, mediastinal, or hilar 
lymph nodes, including locations in the internal mammary 
chains and in the mediastinal fat surrounding the heart.
The patient was scheduled for surgery, and pre-operative 
lymphoscintigraphy was performed. She received an in-
tradermal, peri-areolar administration of  110 μCi of  fil-
tered Technetium 99m sulfur colloid in a volume of  0.1cc 
into the upper outer quadrant of  the left breast, with emis-
sion and transmission imaging of  the chest performed at 30 
minutes. Lymphatics were visualized cranial to the injection 
site at 30 minutes; however, no discrete sentinel node was 
visualized at the time of  imaging (Figs. 2A, 2B).
Following lymphoscintigraphy, the Department of  Nu-
clear Medicine was consulted because the surgeons could 
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Figure 1B. 39-year-old woman with advanced breast cancer 
and nonvisualized sentinel node. FDG PET-CT axial image 
demonstrating the dominant suspicious lobular soft-tissue 
mass in the upper inner quadrant of the left breast, measur-
ing 1.9 cm with a maximum SUV of 9.9. Focal metabolic 
activity was also noted corresponding to a benign-
appearing, 1.4 x 0.9-cm, low-lying left axillary lymph node 
with maximum SUV of 1.6.
Figure 1C. 39-year-old woman with advanced breast cancer 
and nonvisualized sentinel node. FDG PET-CT axial image 
demonstrating a 1.2-cm lymph node deep to the pectoralis 
minor muscle with maximum SUV of 2.3. Figure 2A. 39-year-old woman with advanced breast cancer 
and nonvisualized sentinel node. Emission image obtained 
30 minutes after intradermal, peri-areolar administration of 
110 μCi of filtered Technetium 99m sulfur colloid in a vol-
ume of 0.1cc into the upper outer quadrant of the left breast 
demonstrates migration of tracer in the lymphatics cranial to 
the injection site; however, no sentinel node is visualized at 
the time of imaging.
not detect the sentinel node with the gamma probe in the 
operating room. The gamma detector was recalibrated, 
and surgeons were still unable to localize the sentinel node. 
Upon visual inspection and palpation of  the lymph nodes, 
the surgeon was able to macroscopically detect lymph-node 
disease. The patient underwent a total left mastectomy, and 
pathology revealed one of  the three sentinel-node speci-
mens positive for metastatic carcinoma and six of  the seven 
left axillary lymph nodes positive for metastatic carcinoma. 
Discussion
We hypothesize that although there was migration of  the 
Technetium 99m sulfur colloid by 30 minutes, the tracer 
did not reach the sentinel node by the time of  surgery due 
to advanced disease that obstructed the flow of  lymphatics. 
Such alteration in lymphatic flow as a result of  advanced 
disease has been described previously with regard to mela-
noma, penile cancer, and breast cancer (1, 2). In breast 
cancer, previous studies have shown that an increased 
number of  axillary lymph nodes with metastatic involve-
ment is associated with nonvisualization of  lymph nodes 
during lymphoscintigraphy (3, 4).
Although we believe that the cause of  nonvisualization of 
the sentinel node on lymphoscintigraphy for this patient 
was extensive disease obstructing the lymphatic system, 
many other factors can affect visualization of  lymph nodes 
during lymphoscintigraphy. It has previously been reported 
that age of  the patient and tumor size may influence senti-
nel node detection rates (4, 5). Furthermore, the radio-
pharmaceutical used, the dose of  the pharmaceutical, the 
particle size of  the pharmaceutical, and the injection-to-
imaging time may all influence visualization of  the sentinel 
node during lymphoscintigraphy (1). The site of  pharma-
ceutical injection (whether intratumoral vs. extratumoral, 
intradermal vs. subdermal, or lateral vs. medial to a previ-
ous breast scar) can also affect visualization of  the sentinel 
node during lymphoscintigraphy (6-12). Lastly, it is possible 
that a blue-dye injection in addition to Technetium 99m 
sulfur colloid and a gamma probe would have aided in de-
tection of  the sentinel node for this patient (13-16). Use of  
SPECT imaging in addition to planar imaging may have 
also provided additional information for sentinel-node lo-
calization in this patient (2, 17). 
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Figure 2B. 39-year-old woman with advanced breast cancer 
and nonvisualized sentinel node. Transmission image ob-
tained 30 minutes post-injection also demonstrates migra-
tion of tracer in the lymphatics cranial to the injection site; 
however, no sentinel node is visualized. 
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Figure 5. 27-year-old man with MPNST. Microscopic H & E-
stained specimen shows neurofibromatous component of 
MPNST. There are interlacing wavy bands of collagen, as-
sociated with spindled cells with wavy nuclei and no signifi-
cant pleomorphism. 
Figure 6. 27-year-old man with MPNST. Microscopic H & E-stained specimens of MPNST at medium (A, B), high (C), and low 
(D) power show a hypercellular spindle-cell lesion with cells variably arranged in a herringbone and fascicular pattern. There is 
severe cytologic atypia and nuclear pleomorphism, with focally brisk mitotic activity. No necrosis is present. 
